CSL Announces Robust Immune Response From Single Dose Of Swine Flu Vaccine; TGA Approval Expected Soon
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - CSL Limited announced Sept. 11 that 95 percent of swine flu vaccine clinical trial participants achieved appropriate antibody levels with a single 15 mcg dose of the new Panvax vaccine
You may also be interested in...
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products
Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age